Skip to main content

Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues

Clinical and Translational Oncology volume 11, pages 48–53 (2009)Cite this article

Abstract

Objectives

To evaluate the initial response and outcomes (quality of life and presence of side effects) in patients with advanced neuroendocrine tumours (NET) after treatment with radiolabelled somatostatin analogues: 90Y-DOTAT-yr3-octreotide (90Y-DOTATOC) and 177Lu-DOTA-Tyr3- octreotate (177Lu-DOTATATE).

Material and methods

The study included 5 patients with advanced NET referred to European centres for treatment with 90Y-DOTATOC and 177Lu-DOTATATE after lack of response to conventional treatment. The mean age was 45.6 years (29-68 years). Response to therapy was assessed according to: (1) RECIST criteria, as complete response, partial response, stable disease or disease progression, (2) post-treatment survival time and (3) quality of life, using the Karnofsky performance index.

Results

All patients survived for >20 months after treatment; mean survival time was 28 months. At the time of writing, three of the patients are alive after 20, 26 and 37 months. Partial response was observed in one patient, stable disease in three and disease progression in the fifth patient. A good-to-excellent post-treatment quality of life was observed in all patients.

Conclusion

Therapy with radiolabelled somatostatin analogues showed promising results in patients with advanced NET, with a partial response or disease stabilisation in four of the five patients, who have enjoyed an extended survival period and an improved quality of life.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

39,95 €

Price includes VAT (Finland)

References

  1. Clark O, Ajani JA, Kulke M et al (2005) Neuroendocrine tumors. In: National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology

  2. Barakat MT, Meeran K, Bloom SR (2004) Neuroendocrine tumours. Endocr Relat Cancer 11:1–18

    Article  PubMed  CAS  Google Scholar 

  3. Valdes Olmos RA, Hoefnagel CA, Bais E et al (2001) Avances terapeúticos de medicina nuclear en Oncología. Rev Esp Med Nucl 20:547–557

    Google Scholar 

  4. Cremonesi M, Ferrari M, Zoboli S et al (1999) Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)YDOTATOC. Eur J Nucl Med 26:877–886

    Article  PubMed  CAS  Google Scholar 

  5. Waldherr C, Pless M, Maecke HR et al (2001) The clinical value of [90YDOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12:941–945

    Article  PubMed  CAS  Google Scholar 

  6. Waldherr C, Pless, M, Maecke HR et al (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90YDOTATOC. J Nucl Med 43:610–616

    PubMed  CAS  Google Scholar 

  7. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754–2762

    Article  PubMed  CAS  Google Scholar 

  8. Paganelli G, Zoboli S, Cremonesi M et al (2001) Receptor-mediated radiotherapy with 90Y-DOTADPhe1- Tyr3-octreotide. Eur J Nucl Med 28:426–434

    Article  PubMed  CAS  Google Scholar 

  9. Bodei L, Cremonesi M, Grana C et al (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31:1038–1046

    Article  PubMed  CAS  Google Scholar 

  10. Valkema R, De Jong M, Bakker WH et al (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: The Rotterdam experience. Semin Nucl Med 32:110–122

    Article  PubMed  Google Scholar 

  11. Bodei L, Cremonesi M, Zoboli S et al (2003) Receptor-mediated radionuclide therapy with 90YDOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 30:207–216

    PubMed  CAS  Google Scholar 

  12. Esser JP, Krenning EP, Teunissen JJ et al (2006) Comparison of [(177)Lu-DOTA (0),Tyr (3)]octreotate and [(177)Lu-DOTA (0),Tyr (3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Molec Imaging 33:1346–1351

    Article  CAS  Google Scholar 

  13. Reubi JC, Macke HR, Krenning EP (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46[Suppl 1]:67–75

    Google Scholar 

  14. Rolleman EJ, de Jong M, Valkema R et al (2006) Inhibition of kidney uptake of radiolabeled somatostatin analogues: amino acids or gelofusine? J Nucl Med 47:1730–1731

    PubMed  Google Scholar 

  15. Vegt E, Wetzels JF, Russel FG et al (2006) Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 47:432–436

    PubMed  CAS  Google Scholar 

  16. Behr TM, Behe M, Kluge G et al (2002) Nephrotoxicity versus anti-tumourefficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging 29:277–279

    Article  PubMed  Google Scholar 

  17. Kwekkeboom DJ, Bakker WH, Kooij PP et al (2001) [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 28:1319–1325

    Article  PubMed  CAS  Google Scholar 

  18. Kwekkeboom DJ, Bakker WH, Kam BL et al (2003) Treatment of patients with gastro-enteropancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate [abstract]. Eur J Nucl Med Mol Imaging 30:417–422

    PubMed  CAS  Google Scholar 

  19. Kwekkeboom DJ, Bakker WH, Teunissen JJ et al (2003) Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with neuroendocrine tumors: interim results [abstract]. Eur J Nucl Med Mol Imaging 30[Suppl 2]:231

    Google Scholar 

  20. DeJong M, Valkema R, Jamar F et al (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32:133–140

    Article  PubMed  Google Scholar 

  21. Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46:62–66

    Google Scholar 

  22. Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26: 2124–2130

    Article  PubMed  CAS  Google Scholar 

  23. Breeman WA, de Jong M, Kwekkeboom DJ et al (2001) Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28:1421–1429

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Department and Oncology Department, Virgen de las Nieves University Hospital, Avda. Fuerzas Armadas, 2, ES-18014, Granada, Spain

    María Angustias Muros & Juan Ramón Delgado

  2. San Cecilio University Hospital, Granada, Spain

    Mariela Varsavsky, Pablo Iglesias Rozas & Javier Valdivia

  3. Basel University Hospital, Basel, Switzerland

    Flavio Forrer

  4. European Oncology Institute, Milan, Italy

    Lisa Bodei & Giovanni Paganelli

Authors
  1. María Angustias Muros
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariela Varsavsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pablo Iglesias Rozas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Javier Valdivia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juan Ramón Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Flavio Forrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lisa Bodei
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giovanni Paganelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to María Angustias Muros.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Muros, M.A., Varsavsky, M., Iglesias Rozas, P. et al. Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Clin Transl Oncol 11, 48–53 (2009). https://doi.org/10.1007/s12094-009-0310-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-009-0310-5

Keywords

  • Neuroendocrine tumours
  • Radiolabelled somatostatin analogues
  • 90Y-DOTATOC
  • 177Lu-DOTATATE